CORBUS PHARMACEUTICALS HOLDI (CRBP)
US21833P3010 - Common Stock
Overall CRBP gets a fundamental rating of 0 out of 10. We evaluated CRBP against 568 industry peers in the Biotechnology industry. CRBP has a bad profitability rating. Also its financial health evaluation is rather negative. CRBP is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
CRBP had negative earnings in the past year.
In the past year CRBP has reported a negative cash flow from operations.
CRBP had negative earnings in each of the past 5 years.
CRBP had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CRBP's Return On Assets of -157.72% is on the low side compared to the rest of the industry. CRBP is outperformed by 86.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -157.72% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-88.01%
ROA(5y)-103.66%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CRBP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CRBP has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CRBP has more shares outstanding
The debt/assets ratio for CRBP is higher compared to a year ago.
2.2 Solvency
CRBP has an Altman-Z score of -24.47. This is a bad value and indicates that CRBP is not financially healthy and even has some risk of bankruptcy.
CRBP has a Altman-Z score of -24.47. This is amonst the worse of the industry: CRBP underperforms 89.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -24.47 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CRBP has a Current Ratio of 0.74. This is a bad value and indicates that CRBP is not financially healthy enough and could expect problems in meeting its short term obligations.
CRBP has a Current ratio of 0.74. This is amonst the worse of the industry: CRBP underperforms 91.33% of its industry peers.
A Quick Ratio of 0.74 indicates that CRBP may have some problems paying its short term obligations.
With a Quick ratio value of 0.74, CRBP is not doing good in the industry: 91.33% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
CRBP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.17%, which is quite impressive.
EPS 1Y (TTM)57.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
CRBP is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.94% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y58.19%
EPS Next 2Y19.31%
EPS Next 3Y13.32%
EPS Next 5Y4.94%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
CRBP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CRBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CRBP's earnings are expected to grow with 13.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.31%
EPS Next 3Y13.32%
5. Dividend
5.1 Amount
No dividends for CRBP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CORBUS PHARMACEUTICALS HOLDI
NASDAQ:CRBP (12/20/2024, 8:03:52 PM)
After market: 13 0 (0%)13
-0.33 (-2.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners102.43%
Inst Owner Change10.42%
Ins Owners0.72%
Ins Owner Change-0.02%
Market Cap158.34M
Analysts85.71
Price Target57.91 (345.46%)
Short Float %22.41%
Short Ratio7.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.62%
Min EPS beat(2)2.44%
Max EPS beat(2)24.81%
EPS beat(4)3
Avg EPS beat(4)15.19%
Min EPS beat(4)-1.63%
Max EPS beat(4)35.17%
EPS beat(8)4
Avg EPS beat(8)-7.23%
EPS beat(12)7
Avg EPS beat(12)3.27%
EPS beat(16)9
Avg EPS beat(16)4.1%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.88%
PT rev (3m)-31.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-12.1%
EPS NY rev (3m)-14.99%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.69
EYN/A
EPS(NY)-5.85
Fwd EYN/A
FCF(TTM)-2.96
FCFYN/A
OCF(TTM)-2.96
OCFYN/A
SpS0
BVpS-0.57
TBVpS-0.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -157.72% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-88.01%
ROA(5y)-103.66%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | -24.47 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)2.11%
Cap/Depr(5y)83.89%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.9%
EPS Next Y58.19%
EPS Next 2Y19.31%
EPS Next 3Y13.32%
EPS Next 5Y4.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-29.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5Y-15.19%
FCF growth 1Y3.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.83%
OCF growth 3YN/A
OCF growth 5YN/A